Table 1 Baseline characteristics of cohorts 1 and 2

LL-37 Range (ng/mL)

23–79

12–245

13–94

26–70

21–167

13–282

Age at Collection (mean ± SEM)

46 ± 2

40 ± 2

35 ± 2

43 ± 3

37 ± 1

38 ± 2

Age at diagnosis (mean ± SEM)

35 ± 2

30 ± 2

28 ± 1

25 ± 1

Duration of Disease in Years (mean ± SEM)

6 ± 1

6 ± 1

8 ± 1

13 ± 2

Gender (% Male)

42%

35%

25%

40%

56%

52%

Percentage of patients who used biologics

13%

38%

16%

45%

Percentage of patients who used steroids

17%

52%

32%

30%

Percentage of patients who used immunomodulators

9%

14%

21%

38%

Percentage of patients who used 5-aminosalicyclic acid (5-ASA)

74%

24%

58%

24%

Percentage of Current Smoker (%)

20%

13%

21%

20%

7%

12%

C-reactive protein (CRP) Levels (mg/L) (mean ± SEM)

1.18 ± 0.42

4.77 ± 1.43

0.75 ± 0.16

1.59 ± 0.39

UC Partial Mayo Score (mean ± SEM)

2.09 ± 0.47

3.04 ± 0.29

UC Mayo Endoscopic Score (mean ± SEM)

1.64 ± 0.19

1.13 ± 0.14

UC Partial Mayo Score 6–18 months later (mean ± SEM)

2.40 ± 0.52

1.59 ± 0.28

UC ulcerative proctitis E1 (%)

38%

16%

UC left sided colitis E2 (%)

24%

59%

UC pancolitis E3 (%)

29%

22%

CD Harvey Bradshaw Index (mean ± SEM)

3.67 ± 0.77

4.22 ± 0.44

CD Harvey Bradshaw Index 6–18 months later (mean ± SEM)

2.54 ± 0.65

1.38 ± 0.26

CD Age at diagnosis less than 16 years A1 %

12%

27%

CD Age at diagnosis 17–40 years A2 %

59%

60%

CD Age at diagnosis over 40 years A3 %

29%

12%

CD ileal L1 (%)

56%

23%

CD colonic L2 (%)

6%

15%

CD ilealcolonic L3 (%)

38%

63%

CD isolated upper digestive tract L4 (%)

13%

7%

CD non-stricturing, non-penetrating B1 (%)

43%

57%

CD stricturing B2 (%)

50%

24%

CD penetrating B3 (%)

11%

27%

CD perianal disease P (%)

11%

0%

50

23

28

20

57

67